Turning vision into
relentless execution
Leadership team
Alok Malik
President & Business Head – India Formulations
Mr. Alok Malik is President & Business Head of India Formulations at Glenmark Pharmaceuticals. He drives our India Formulations and Nepal business across multiple therapy areas, including Dermatology, Respiratory, Oncology, Critical Care, Cardio-metabolic, Govt. Institutions, Generics and Consumer.
With over thirty years of experience in managing the life cycle of pharmaceutical brands, he has successfully launched over a hundred products across major therapy areas in the Indian pharmaceutical market. He has played a key role in facilitating seamless business transitions, following mergers and brand acquisitions.
Before joining Glenmark in 2018, he served as Country Head for Abbott’s diagnostic business in India. He spent over a decade combined at Abbott and Piramal Healthcare in various roles. He holds a degree in science and an MBA from the University of Indore.
India Formulations
Alok Malik
President & Business Head – India Formulations
Mr. Alok Malik is President & Business Head of India Formulations at Glenmark Pharmaceuticals. He drives our India Formulations and Nepal business across multiple therapy areas, including Dermatology, Respiratory, Oncology, Critical Care, Cardio-metabolic, Govt. Institutions, Generics and Consumer.
With over thirty years of experience in managing the life cycle of pharmaceutical brands, he has successfully launched over a hundred products across major therapy areas in the Indian pharmaceutical market. He has played a key role in facilitating seamless business transitions, following mergers and brand acquisitions.
Before joining Glenmark in 2018, he served as Country Head for Abbott’s diagnostic business in India. He spent over a decade combined at Abbott and Piramal Healthcare in various roles. He holds a degree in science and an MBA from the University of Indore.
Marc T. Kikuchi
President & Business Head – North America
Mr. Marc Kikuchi is President & Business Head of North America at Glenmark Pharmaceuticals. He oversees operations, strategic initiatives, and our growth portfolio in the region.
He has held various roles of increasing responsibility across the pharmaceutical industry. Having over thirty years of experience, he worked with Dr. Reddy’s Laboratories before joining Glenmark in 2024, and has also been associated with Zydus Pharmaceuticals and AmerisourceBergen Corporation, among other organizations.
He holds a degree in Molecular and Cell Biology from the University of California, Berkeley, and an MBA from Carnegie Mellon University.
North America
Marc T. Kikuchi
President & Business Head – North America
Mr. Marc Kikuchi is President & Business Head of North America at Glenmark Pharmaceuticals. He oversees operations, strategic initiatives, and our growth portfolio in the region.
He has held various roles of increasing responsibility across the pharmaceutical industry. Having over thirty years of experience, he worked with Dr. Reddy’s Laboratories before joining Glenmark in 2024, and has also been associated with Zydus Pharmaceuticals and AmerisourceBergen Corporation, among other organizations.
He holds a degree in Molecular and Cell Biology from the University of California, Berkeley, and an MBA from Carnegie Mellon University.
Christoph Stoller
President & Business Head – Europe & Emerging Markets
Mr. Christoph Stoller is President & Business Head of Europe & Emerging Markets at
Glenmark Pharmaceuticals. He provides strategic leadership to enhance focus and
alignment across Europe and emerging markets, including Asia, Russia/CIS, the
Middle East, Africa and Latin America, aiming to better address patient needs.
With over twenty-five years of experience, he has successfully led and transformed
businesses for growth across multiple geographies.
Before joining Glenmark, he was General Manager for Teva´s Germany and Austria cluster
and served as Chief Operating Officer – Global Generic Medicines, Europe.
He was also President and Board Member of Medicines for Europe, an association
representing nearly 70% of the pharmaceutical supply in Europe. His previous roles
include significant positions at Zur Rose Group, Helvepharm, DSM,
F. Hoffmann-La Roche, and Swiss Re.
He holds a degree in Business Administration from the University of St. Gallen,
Switzerland (lic.oec.HSG).
Europe & Emerging Markets
Christoph Stoller
President & Business Head – Europe & Emerging Markets
Mr. Christoph Stoller is President & Business Head of Europe & Emerging Markets at
Glenmark Pharmaceuticals. He provides strategic leadership to enhance focus and
alignment across Europe and emerging markets, including Asia, Russia/CIS, the
Middle East, Africa and Latin America, aiming to better address patient needs.
With over twenty-five years of experience, he has successfully led and transformed
businesses for growth across multiple geographies.
Before joining Glenmark, he was General Manager for Teva´s Germany and Austria cluster
and served as Chief Operating Officer – Global Generic Medicines, Europe.
He was also President and Board Member of Medicines for Europe, an association
representing nearly 70% of the pharmaceutical supply in Europe. His previous roles
include significant positions at Zur Rose Group, Helvepharm, DSM,
F. Hoffmann-La Roche, and Swiss Re.
He holds a degree in Business Administration from the University of St. Gallen,
Switzerland (lic.oec.HSG).
Nishan de Silva
Global Strategy Advisor
Mr. Nishan de Silva, M.D., M.B.A. is a life sciences executive, investor, and board member with 25+ years of experience spanning life sciences strategy, finance, and operations across management consulting, private equity, and C-suite/board roles in public and venture-backed biopharmaceutical companies.
He began his career at McKinsey & Company and later spent eight years at Warburg Pincus, where he led and supported multiple biopharma investments and served on portfolio company Boards. He has held senior operating roles including CFO & Head of Strategy at Ligand Pharmaceuticals, President & COO at Poseida Therapeutics, where he started as the second employee and which was acquired by Roche for $1.5B, as well as CEO roles at AFYX Therapeutics and Radionetics Oncology, two venture-backed biotechnology companies.
Dr. de Silva currently serves on the boards of Cartesian Therapeutics (NASDAQ: RNAC) and Biotech Vegas.
He holds degrees from Harvard (A.B. Summa Cum Laude), the University of Pennsylvania School of Medicine (M.D.), and Wharton (M.B.A. with distinction).
Nishan de Silva
Global Strategy Advisor
Mr. Nishan de Silva, M.D., M.B.A. is a life sciences executive, investor, and board member with 25+ years of experience spanning life sciences strategy, finance, and operations across management consulting, private equity, and C-suite/board roles in public and venture-backed biopharmaceutical companies.
He began his career at McKinsey & Company and later spent eight years at Warburg Pincus, where he led and supported multiple biopharma investments and served on portfolio company Boards. He has held senior operating roles including CFO & Head of Strategy at Ligand Pharmaceuticals, President & COO at Poseida Therapeutics, where he started as the second employee and which was acquired by Roche for $1.5B, as well as CEO roles at AFYX Therapeutics and Radionetics Oncology, two venture-backed biotechnology companies.
Dr. de Silva currently serves on the boards of Cartesian Therapeutics (NASDAQ: RNAC) and Biotech Vegas.
He holds degrees from Harvard (A.B. Summa Cum Laude), the University of Pennsylvania School of Medicine (M.D.), and Wharton (M.B.A. with distinction).
Lida Pacaud, M.D.
Interim CEO - Ichnos Glenmark Innovation
Ms. Lida Pacaud, M.D. is an accomplished physician and expert in oncology drug development. She has served as medical lead for clinical development strategies and execution of phase one to phase three programs.
Lida has successfully delivered clearance of several Investigational New Drug applications for first-in-human CAR-T cell programs, and has extensive experience with health authority interactions for marketing authorization submissions and approvals.
Prior to joining Ichnos, Lida served as Vice President, Head of Clinical Development and Medical Affairs, at Legend Biotech, where she led the Janssen J&J partnership for global development of CARVYKTI (BCMA CAR-T) and established the company’s clinical capabilities for early portfolio pipelines (except China territory).
She also previously worked on development of KYMRIAH (CD19 CAR-T) and AFINITOR (mTOR kinase inhibitor) at Novartis, and AVASTIN (VEGF inhibitor mAb) at Hoffman la Roche.
Lida received her medical degree and a certification in paediatrics from Tbilisi State Medical University in Georgia, and served as a clinical research physician and investigator at Robert-Debré Hospital in Paris.
Ichnos Glenmark Innovation
Lida Pacaud, M.D.
Interim CEO - Ichnos Glenmark Innovation
Ms. Lida Pacaud, M.D. is an accomplished physician and expert in oncology drug development. She has served as medical lead for clinical development strategies and execution of phase one to phase three programs.
Lida has successfully delivered clearance of several Investigational New Drug applications for first-in-human CAR-T cell programs, and has extensive experience with health authority interactions for marketing authorization submissions and approvals.
Prior to joining Ichnos, Lida served as Vice President, Head of Clinical Development and Medical Affairs, at Legend Biotech, where she led the Janssen J&J partnership for global development of CARVYKTI (BCMA CAR-T) and established the company’s clinical capabilities for early portfolio pipelines (except China territory).
She also previously worked on development of KYMRIAH (CD19 CAR-T) and AFINITOR (mTOR kinase inhibitor) at Novartis, and AVASTIN (VEGF inhibitor mAb) at Hoffman la Roche.
Lida received her medical degree and a certification in paediatrics from Tbilisi State Medical University in Georgia, and served as a clinical research physician and investigator at Robert-Debré Hospital in Paris.
Ulhas Dhuppad
President & Head – Global Pharmaceutical Development
Mr. Ulhas Dhuppad is President & Head of Global Pharmaceutical Development at
Glenmark Pharmaceuticals. He oversees generics research, specialty formulations,
global regulatory affairs, project management and the Bio Equivalence Centre.
With over thirty-four years of experience, he has developed more than 300 products, including complex generics for the USA and Europe markets, and specialty products for global markets.
He has played a key role in designing development strategies, successfully filing niche products,
and developing complex dosage forms. His expertise includes establishing systems for robust
and timely product development.
He has held significant roles at Cadila Laboratories, Cipla, Lupin, Morepen and
Alkem Laboratories. He has been working with Glenmark for 18 years, leading CMC
development and contributing to building the Global Formulations R&D function.
He holds a Master’s Degree in Pharmacy from Pune University.
Global Pharmaceutical Development
Ulhas Dhuppad
President & Head – Global Pharmaceutical Development
Mr. Ulhas Dhuppad is President & Head of Global Pharmaceutical Development at
Glenmark Pharmaceuticals. He oversees generics research, specialty formulations,
global regulatory affairs, project management and the Bio Equivalence Centre.
With over thirty-four years of experience, he has developed more than 300 products, including complex generics for the USA and Europe markets, and specialty products for global markets.
He has played a key role in designing development strategies, successfully filing niche products,
and developing complex dosage forms. His expertise includes establishing systems for robust
and timely product development.
He has held significant roles at Cadila Laboratories, Cipla, Lupin, Morepen and
Alkem Laboratories. He has been working with Glenmark for 18 years, leading CMC
development and contributing to building the Global Formulations R&D function.
He holds a Master’s Degree in Pharmacy from Pune University.
Marco Cerato
EVP Global Head – Innovative Business
Mr. Marco Cerato is Executive Vice President & Global Head of Portfolio, Innovative
Business at Glenmark Pharmaceuticals. He brings close to two decades of
experience in the biotech and pharmaceutical industry, starting as a researcher and
advancing to his current profile.
He has had vast experience in managing global teams in Corporate and Business Development, as well as Alliance and Portfolio Management across complex organizations. He is passionate about building differentiated portfolios and finding avenues to deliver innovation for patients.
Prior to joining Glenmark, he was part of the executive team of Mundipharma as the
Senior Vice President and Global Head of Corporate, Business Development and
Alliance Management. Prior to that he has held roles of increasing responsibility in
leading organizations like Helsinn Healthcare, Aptalis Pharma and Eurand S.p.A.
He holds a Master’s Degree in Industrial Biotechnologies from Milano Bicocca
University and a Master’s in Business Administration from SDA Bocconi.
Innovative Business
Marco Cerato
EVP Global Head – Innovative Business
Mr. Marco Cerato is Executive Vice President & Global Head of Portfolio, Innovative
Business at Glenmark Pharmaceuticals. He brings close to two decades of
experience in the biotech and pharmaceutical industry, starting as a researcher and
advancing to his current profile.
He has had vast experience in managing global teams in Corporate and Business Development, as well as Alliance and Portfolio Management across complex organizations. He is passionate about building differentiated portfolios and finding avenues to deliver innovation for patients.
Prior to joining Glenmark, he was part of the executive team of Mundipharma as the
Senior Vice President and Global Head of Corporate, Business Development and
Alliance Management. Prior to that he has held roles of increasing responsibility in
leading organizations like Helsinn Healthcare, Aptalis Pharma and Eurand S.p.A.
He holds a Master’s Degree in Industrial Biotechnologies from Milano Bicocca
University and a Master’s in Business Administration from SDA Bocconi.
Brijlal Motwani
President & Global Head – Formulation Operations
Mr. Brijlal Motwani is President & Global Head – Formulation Operations at
Glenmark Pharmaceuticals. He oversees demand and supply planning, procurement,
project management, and strategic change management initiatives, at eleven state-of-the-art
manufacturing facilities across India, the USA, Argentina and the Czech Republic.
With over three decades of experience in Manufacturing and Operations, he has led
operations transformation programs for leading pharmaceutical organizations, both in
India and internationally. He has been instrumental in enhancing productivity,
streamlining operations, and developing long-term supply chain strategies. He has successfully guided multiple organisations through regulatory audits such as theU.S. FDA, MHRA, and ANVISA.
Before joining Glenmark in 2019, he was the Manufacturing Cluster Head at Zydus
Lifesciences, overseeing several sites in India, the USA and Brazil. He also served as
Regional Manufacturing Head at Sun Pharma, managing manufacturing sites in
Africa, and has held positions with Ranbaxy Laboratories, Dr. Reddy’s Laboratories,
Cipla and Macleods Pharmaceuticals across various locations in India and abroad.
He holds a postgraduate degree in Pharmacy from Nagpur University.
Formulation Operations
Brijlal Motwani
President & Global Head – Formulation Operations
Mr. Brijlal Motwani is President & Global Head – Formulation Operations at
Glenmark Pharmaceuticals. He oversees demand and supply planning, procurement,
project management, and strategic change management initiatives, at eleven state-of-the-art
manufacturing facilities across India, the USA, Argentina and the Czech Republic.
With over three decades of experience in Manufacturing and Operations, he has led
operations transformation programs for leading pharmaceutical organizations, both in
India and internationally. He has been instrumental in enhancing productivity,
streamlining operations, and developing long-term supply chain strategies. He has successfully guided multiple organisations through regulatory audits such as theU.S. FDA, MHRA, and ANVISA.
Before joining Glenmark in 2019, he was the Manufacturing Cluster Head at Zydus
Lifesciences, overseeing several sites in India, the USA and Brazil. He also served as
Regional Manufacturing Head at Sun Pharma, managing manufacturing sites in
Africa, and has held positions with Ranbaxy Laboratories, Dr. Reddy’s Laboratories,
Cipla and Macleods Pharmaceuticals across various locations in India and abroad.
He holds a postgraduate degree in Pharmacy from Nagpur University.
Indrajit Bose
President & Chief Quality Officer
Mr. Indrajit Bose is President & Chief Quality Officer at Glenmark Pharmaceuticals.
He heads the Quality function for Glenmark’s eleven state-of-the-art manufacturing facilities
across India, the USA, Argentina and the Czech Republic.
He brings with him over thirty years of rich and varied experience in the pharmaceutical industry, across quality and manufacturing of formulations and active pharmaceutical ingredients (API).
He has successfully guided various organizations through regulatory audits like
the U.S. FDA, MHRA, and ANVISA.
Before joining Glenmark in 2022, he headed global quality and compliance for Dr.
Reddy’s Laboratories. He has also held senior leadership roles across leading
pharmaceutical companies like Lupin, Alembic, Medley, IPCA and ORGANON.
He is a Pharmacy graduate from Birla Institute of Management, Mesra, Ranchi, and
has completed his P.G.D.M. from Brilliant School of Management, Chennai.
Chief Quality Officer
Indrajit Bose
President & Chief Quality Officer
Mr. Indrajit Bose is President & Chief Quality Officer at Glenmark Pharmaceuticals.
He heads the Quality function for Glenmark’s eleven state-of-the-art manufacturing facilities
across India, the USA, Argentina and the Czech Republic.
He brings with him over thirty years of rich and varied experience in the pharmaceutical industry, across quality and manufacturing of formulations and active pharmaceutical ingredients (API).
He has successfully guided various organizations through regulatory audits like
the U.S. FDA, MHRA, and ANVISA.
Before joining Glenmark in 2022, he headed global quality and compliance for Dr.
Reddy’s Laboratories. He has also held senior leadership roles across leading
pharmaceutical companies like Lupin, Alembic, Medley, IPCA and ORGANON.
He is a Pharmacy graduate from Birla Institute of Management, Mesra, Ranchi, and
has completed his P.G.D.M. from Brilliant School of Management, Chennai.
Samir Kazi
EVP & Head – Legal, Compliance & Intellectual Property
Mr. Samir Kazi is Executive Vice President, and Head of Legal, Compliance &
Intellectual Property at Glenmark Pharmaceuticals. He is responsible for upholding
high standards of ethics and business conduct within our organization.
He has over twenty-four years of global experience in corporate consulting, compliance,
litigation, legal affairs, risk management, and M&A across various industries.
He has worked with Pfizer India, the Hinduja Group, Mulla & Mulla, and Craigie
Blunt & Caroe.
He holds a Bachelor’s degree in Legislative Law from Mumbai University, as well as
a BCom in Financial Accountancy and Taxation.
Legal, Compliance & IP
Samir Kazi
EVP & Head – Legal, Compliance & Intellectual Property
Mr. Samir Kazi is Executive Vice President, and Head of Legal, Compliance &
Intellectual Property at Glenmark Pharmaceuticals. He is responsible for upholding
high standards of ethics and business conduct within our organization.
He has over twenty-four years of global experience in corporate consulting, compliance,
litigation, legal affairs, risk management, and M&A across various industries.
He has worked with Pfizer India, the Hinduja Group, Mulla & Mulla, and Craigie
Blunt & Caroe.
He holds a Bachelor’s degree in Legislative Law from Mumbai University, as well as
a BCom in Financial Accountancy and Taxation.
Alind Sharma
President & Chief Human Resources Officer
Mr. Alind Sharma is President & Chief Human Resources Officer at Glenmark Pharmaceuticals.
He drives organizational advancement through human capital strategy. His areas of focus include talent development, leadership development, and talent engagement.
He re-joined Glenmark, having previously worked with the company from 2002 to 2010.
Before taking up his current role, he was the Vice President of Human Capital at Optum,
part of United Health Group. He has also held senior positions at Pfizer, Monsanto,
Tata International and Ranbaxy.
He is a Post-Graduate from Indian Institute of Management, Ahmedabad, India.
Chief Human Resources Officer
Alind Sharma
President & Chief Human Resources Officer
Mr. Alind Sharma is President & Chief Human Resources Officer at Glenmark Pharmaceuticals.
He drives organizational advancement through human capital strategy. His areas of focus include talent development, leadership development, and talent engagement.
He re-joined Glenmark, having previously worked with the company from 2002 to 2010.
Before taking up his current role, he was the Vice President of Human Capital at Optum,
part of United Health Group. He has also held senior positions at Pfizer, Monsanto,
Tata International and Ranbaxy.
He is a Post-Graduate from Indian Institute of Management, Ahmedabad, India.
Edsel Pereira
EVP – Information Technology
Mr. Edsel Pereira is Executive Vice President – Information Technology at Glenmark
Pharmaceuticals. He oversees the Global IT function and serves as a crucial interface
between business and IT.
With over 35 years of experience, he has been with Glenmark since 2012. He also
worked with Glenmark previously, from 1990 to 2005. Before re-joining Glenmark in 2012,
he was Corporate Director IT at Hikma Pharmaceuticals PLC, UK.
He holds a Master of Management Studies in Finance from the University of Pune, a
Diploma in Marketing Management, and is a Certified Information Systems Auditor
(CISA).
Information Technology
Edsel Pereira
EVP – Information Technology
Mr. Edsel Pereira is Executive Vice President – Information Technology at Glenmark
Pharmaceuticals. He oversees the Global IT function and serves as a crucial interface
between business and IT.
With over 35 years of experience, he has been with Glenmark since 2012. He also
worked with Glenmark previously, from 1990 to 2005. Before re-joining Glenmark in 2012,
he was Corporate Director IT at Hikma Pharmaceuticals PLC, UK.
He holds a Master of Management Studies in Finance from the University of Pune, a
Diploma in Marketing Management, and is a Certified Information Systems Auditor
(CISA).
Shweta Munjal
Chief Communications & CSR
Ms. Shweta Munjal is the Chief Communications & CSR Officer at Glenmark Pharmaceuticals.
She brings over 21 years of diverse, global experience across a spectrum of industries,
including Pharmaceuticals, Financial Services, FMCG, Retail and Technology.
An internationally certified Mediator and a seasoned Values and Culture coach, her career
is marked by her profound expertise in Corporate Marketing, Corporate Communications,
Branding, Digital Media, ESG and CSR.
Prior to joining Glenmark, she excelled in leading Brand, Communications & Sustainability
initiatives at Lupin. Her career includes pivotal roles at Nayara Energy, Thomson Reuters,
Mondelez International, Intuit India, Tesco, Yahoo and NASSCOM, where she consistently demonstrated her strategic acumen and leadership in driving impactful marketing and
communication strategies and sustainability initiatives.
She holds a Bachelor’s degree in Economics and Masters in Mass Communication
from the University of Delhi.
CSR
Shweta Munjal
Chief Communications & CSR
Ms. Shweta Munjal is the Chief Communications & CSR Officer at Glenmark Pharmaceuticals.
She brings over 21 years of diverse, global experience across a spectrum of industries,
including Pharmaceuticals, Financial Services, FMCG, Retail and Technology.
An internationally certified Mediator and a seasoned Values and Culture coach, her career
is marked by her profound expertise in Corporate Marketing, Corporate Communications,
Branding, Digital Media, ESG and CSR.
Prior to joining Glenmark, she excelled in leading Brand, Communications & Sustainability
initiatives at Lupin. Her career includes pivotal roles at Nayara Energy, Thomson Reuters,
Mondelez International, Intuit India, Tesco, Yahoo and NASSCOM, where she consistently demonstrated her strategic acumen and leadership in driving impactful marketing and
communication strategies and sustainability initiatives.
She holds a Bachelor’s degree in Economics and Masters in Mass Communication
from the University of Delhi.